Technology & Innovation

SHERIDAN, WYOMING - December 4, 2025 - Info-Tech Research Group has released its 2025 Network Monitoring Data Quadrant Report, spotlighting six user-rated "champion" platforms that promise deeper visibility, faster incident response and stronger operational resilience for enterprise networks. Built entirely on verified end-user feedback from its SoftwareReviews platform, the new rankings give CIOs and network leaders a peer-validated lens on which tools are delivering real value in increasingly complex and threat-exposed environments.

Data-Driven Rankings for an Always-On Network Economy

SHERIDAN, WYOMING - December 4, 2025 - Blend360 has been named Sustainability Partner of the Year - LATAM and Public Sector Solution Provider Program Partner of the Year in the 2025 AWS Partner Awards, highlighting how AI- and cloud-driven analytics are moving to the center of sustainability and public sector modernization across Latin America and beyond. Announced at AWS re:Invent in Las Vegas, the dual recognition positions Blend360 as a key services partner for governments and institutions looking to use Amazon Web Services (AWS) for climate resilience and better resource allocation.

AWS Honors Partners Driving Innovation and Real-World Impact

SHERIDAN, WYOMING - December 4, 2025 - Workday has secured its position as a four-time Leader in the 2025 Gartner® Magic Quadrant™ for Financial Planning Software, underscoring how the company's AI-enabled platform is becoming a strategic hub for finance teams navigating volatility, pricing pressure and tighter capital markets. The recognition highlights Workday Adaptive Planning's role in helping financial planning and analysis (FP&A) organizations shift from static budgeting to always-on, scenario-based planning.

Four Years as a Gartner Leader in Financial Planning

SHERIDAN, WYOMING - December 4, 2025 - Ubicquia has unveiled a coordinated next-generation smart streetlighting portfolio built around its new UbiCell® Micro controller, major enhancements to the UbiVu® infrastructure management platform and the launch of UbiScout™, an AI video accessory that turns existing streetlights into multi-purpose urban sensors for safety, mobility and energy efficiency.

Integrated portfolio targets utilities and cities under pressure to modernize

With grid operators and municipalities facing rising energy costs, decarbonization targets and aging infrastructure, Ubicquia's new offering is designed to make large-scale modernization of streetlighting networks faster and more manageable. The company positions the portfolio as a way to deliver asset intelligence, remote control and AI analytics without wholesale replacement of installed luminaires.

SHERIDAN, WYOMING - December 4, 2025 - Vortex Control Technologies (VCT) has signed a fleet-wide retrofit agreement with Norwegian to equip all Boeing 737-800 aircraft with its patented Finlet fuel-saving modification, aligning the Nordic carrier's cost discipline with a more aggressive sustainability strategy in short- and medium-haul aviation.

Aerodynamic retrofits move from trial to fleet standard

Under the new agreement, Norwegian will install VCT Finlets across its entire 737-800 fleet, following in the footsteps of early adopters such as Avelo Airlines, SunExpress and the U.S. Air Force. The deal marks a pivot from pilot programs to full-fleet deployment, signaling growing confidence among operators that incremental aerodynamic improvements can deliver material savings at scale.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is expanding its Cell Line Development Center of Excellence through a new partnership with ATUM, integrating the Leap-In Transposase® expression platform to help biopharma developers move monoclonal antibodies and complex next-generation biologics into the clinic faster and more cost-effectively.

New options for faster, more flexible cell line development

As pressure grows to launch high-value biologics at lower cost, drug sponsors are looking for cell line development (CLD) solutions that combine speed, robustness and scalability. AGC Biologics' collaboration with ATUM adds a modern transposase-based expression platform to its CLD toolkit, creating a menu of fit-for-purpose options for standard monoclonals, multi-specific antibodies and other complex molecules.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a new manufacturing agreement with AAVantgarde Bio to produce dual-vector AAV gene therapies for Stargardt disease and retinitis pigmentosa, positioning its BravoAAV™ platform at the center of next-generation treatments for inherited retinal disorders with no approved therapies.

Dual-vector AAV platform targets previously "untreatable" retinal genes

Under the deal, AGC Biologics will provide GMP manufacturing for AAVantgarde's two clinical-stage candidates: AAVB-039 for Stargardt disease, the most common inherited form of macular degeneration in children and young adults, and AAVB-081 for retinitis pigmentosa caused by Usher syndrome type 1B. Both programs are in Phase 1/2 trials, with AAVB-039 being tested in the U.S., UK and Europe, and AAVB-081 representing the first-ever dual AAV gene therapy in an ocular indication.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics has signed a strategic development and manufacturing agreement with Repair Biotechnologies to advance a novel mRNA therapeutic aimed at rapidly stabilizing and shrinking atherosclerotic plaques, addressing what both partners describe as the leading single cause of human mortality worldwide.

Targeting plaque biology in a high-burden cardiovascular market

The collaboration focuses on an mRNA-based therapy designed to stabilize and reduce atherosclerotic plaques in major blood vessels, directly tackling the root pathology behind heart attacks and strokes. Rupture of unstable plaque and subsequent thrombotic events account for an estimated 27% of all human deaths, underscoring the strategic importance of any technology capable of reversing or halting plaque progression.

SHERIDAN, WYOMING - December 3, 2025 - AGC Biologics is partnering with public benefit company Rarity PBC to bring a potentially life-saving gene therapy for Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID) through commercial manufacturing and toward FDA approval, underscoring how CDMO collaborations are becoming central to translating academic breakthroughs into scalable rare disease treatments.

From transformational trials to a U.S. commercial pathway

Under the new agreement, AGC Biologics will provide end-to-end development and GMP manufacturing for Rarity's ex vivo autologous gene therapy RDP-101. If approved, RDP-101 would become the first gene therapy commercially available in the United States to reverse ADA-SCID, a rare inherited immunodeficiency that leaves infants dangerously exposed to severe, recurrent infections.

SHERIDAN, WYOMING - December 2, 2025 - Ricoh has introduced its new IM Cxx01CE A3 color multifunction series, positioning the IM C2501CE, IM C3501CE and IM C5501CE as a new sustainability benchmark for office print fleets by combining high reuse rates, lower CO₂ footprint and upgraded security with cloud-ready workflows.

Circular-economy design with high reuse and lower CO₂ footprint

Developed explicitly with circular-economy principles in mind, the new IM Cxx01CE models are manufactured using over 86% reused components and deliver a CO₂ footprint reduced by around 50% compared to comparable multifunction systems. By building on existing hardware resources and refreshing them with the latest security and performance elements, Ricoh enables customers to pursue sustainability targets while maintaining familiar functionality and reliability.